Recombinant ovine atadenovirus induces a strong and sustained T cell response against the hepatitis C virus NS3 antigen in mice

Vaccine

Volumn 22, Issue 21-22, 2004, Pages 2717-2721

  Wüest, Thomas ^a   Both, Gerald W ^b   Prince, Alfred M ^c   Hofmann, Christian ^a   Löser, Peter ^a,d,e  

^a DeveloGen AG   (Germany)

^b CSIRO   (Australia)

^c NEW YORK BLOOD CENTER   (United States)

^d HUMBOLDT UNIVERSITY   (Germany)

^e ROBERT KOCH INSTITUTE   (Germany)

Author keywords

Hepatitis C virus; IFN ELISpot; Ovine atadenovirus; T cell immunity

Indexed keywords

GAMMA INTERFERON; NONSTRUCTURAL PROTEIN 3; UNCLASSIFIED DRUG; VIRUS ANTIGEN; VIRUS VECTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CYTOKINE RELEASE; ENZYME LINKED IMMUNOSPOT ASSAY; GENE CASSETTE; GENE EXPRESSION; GENOME; HEPATITIS C VIRUS; IMMUNE RESPONSE; MOUSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE;

ADENOVIRIDAE; ANIMALS; ANTIBODY SPECIFICITY; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; HUMANS; IMMUNITY, CELLULAR; INTERFERON TYPE II; MICE; MICE, INBRED BALB C; SHEEP; SPLEEN; T-LYMPHOCYTES; VACCINES, SYNTHETIC; VIRAL NONSTRUCTURAL PROTEINS;

EID: 2342607303     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2004.01.048     Document Type: Article

References (30)

1. Alter M.J. Epidemiology of hepatitis C. Hepatology. 26(3 Suppl 1):1997;62S-65S
2. Lauer G.M., Walker B.D. Hepatitis C virus infection. N. Engl. J. Med. 345(1):2001;41-52
3. Saito I., Miyamura T., Ohbayashi A., Harada H., Katayama T., Kikuchi S., et al. Hepatitis C virus infection is associated with the development of hepatocellular carcinoma. Proc. Natl. Acad. Sci. U.S.A. 87(17):1990;6547-6549
4. Gretch D., Corey L., Wilson J., dela Rosa C., Willson R., Carithers R Jr., et al. Assessment of hepatitis C virus RNA levels by quantitative competitive RNA polymerase chain reaction: high-titer viremia correlates with advanced stage of disease. J. Infect. Dis. 169(6):1994;1219-1225
5. Cooper S., Erickson A.L., Adams E.J., Kansopon J., Weiner A.J., Chien D.Y., et al. Analysis of a successful immune response against hepatitis C virus. Immunity. 10(4):1999;439-449
6. Lechner F., Wong D.K., Dunbar P.R., Chapman R., Chung R.T., Dohrenwend P., et al. Analysis of successful immune responses in persons infected with hepatitis C virus. J. Exp. Med. 191(9):2000;1499-1512
7. Takaki A., Wiese M., Maertens G., Depla E., Seifert U., Liebetrau A., et al. Cellular immune responses persist and humoral responses decrease two decades after recovery from a single-source outbreak of hepatitis C. Nat. Med. 6(5):2000;578-582
8. Rehermann B., Chang K.M., McHutchison J.G., Kokka R., Houghton M., Chisari F.V. Quantitative analysis of the peripheral blood cytotoxic T lymphocyte response in patients with chronic hepatitis C virus infection. J. Clin. Invest. 98(6):1996;1432-1440
9. Anthony D.D., Post A.B., Valdez H., Peterson D.L., Murphy M., Heeger P.S. ELISPOT analysis of hepatitis C virus protein-specific IFN-gamma-producing peripheral blood lymphocytes in infected humans with and without cirrhosis. Clin. Immunol. 99(2):2001;232-240
10. Hempel G., Galle P.R., Lohr H.F. Quantitative analysis of specific Th1/Th2 helper cell responses and IgG subtype antibodies in interferon-alpha- treated patients with chronic hepatitis C. J. Med. Virol. 64(3):2001;340-349
11. Vertuani S., Bazzaro M., Gualandi G., Micheletti F., Marastoni M., Fortini C., et al. Effect of interferon-alpha therapy on epitope-specific cytotoxic T lymphocyte responses in hepatitis C virus-infected individuals. Eur. J. Immunol. 32(1):2002;144-154
12. Bassett S.E., Guerra B., Brasky K., Miskovsky E., Houghton M., Klimpel G.R., et al. Protective immune response to hepatitis C virus in chimpanzees rechallenged following clearance of primary infection. Hepatology. 33(6):2001;1479-1487
13. Major M.E., Mihalik K., Puig M., Rehermann B., Nascimbeni M., Rice C.M., et al. Previously infected and recovered chimpanzees exhibit rapid responses that control hepatitis C virus replication upon rechallenge. J. Virol. 76(13):2002;6586-6595
14. Xu Z.Z., Hyatt A., Boyle D.B., Both G.W. Construction of ovine adenovirus recombinants by gene insertion or deletion of related terminal region sequences. Virology. 230(1):1997;62-71
15. Löser P, Kümin D, Hillgenberg M, Both GW, Hofmann C. Preparation of ovine adenovirus vectors. In: Morgan JR (Ed.). Methods in molecular medicine, Gene therapy protocols, 2nd ed., vol. 69. Humana Press: Totawa, 2002; p. 415-26.
16. Löser P., Hofmann C., Both G.W., Uckert W., Hillgenberg M. Construction, rescue and characterisation of vectors derived from ovine atadenoviruses. J. Virol. 77:2003;11941-11951
17. Quade K. Transformation of mammalian cells by avian myelocytomatosis virus and avian erythroblastosis virus. Virology. 98:1979;461-465
18. Löser P., Cichon G., Jennings G.S., Both G.W., Hofmann C. Ovine adenovirus vectors promote efficient gene delivery in vivo. Gene Therapy and Molecular Biology. 4:1999;33-43
19. Power C.A., Grand C.L., Ismail N., Peters N.C., Yurkowski D.P., Bretscher P.A. A valid ELISPOT assay for enumeration of ex vivo, antigen-specific, IFNgamma-producing T cells. J. Immunol. Methods. 227(1-2):1999;99-107
20. Khatri A., Xu Z.Z., Both G.W. Gene expression by atypical recombinant ovine adenovirus vectors during abortive infection of human and animal cells in vitro. Virology. 239(1):1997;226-237
21. Kümin D., Hofmann C., Rudolph M., Both G.W., Löser P. Biology of ovine adenovirus infection of non-permissive cells. J. Virol. 76(21):2002;10882-10893
22. Hofmann C., Löser P., Cichon G., Arnold W., Both G.W., Strauss M. Ovine adenovirus vectors overcome preexisting humoral immunity against human adenoviruses in vivo. J. Virol. 73(8):1999;6930-6936
23. Löser P., Hillgenberg M., Arnold W., Both G.W., Hofmann C. Ovine adenovirus vectors mediate efficient gene transfer to skeletal muscle. Gene Ther. 7(17):2000;1491-1498
24. Voeks D., Martiniello-Wilks R., Madden V., Smith K., Bennetts E., Both G.W., et al. Gene therapy for prostate cancer delivered by ovine adenovirus and mediated by purine nucleoside phosphorylase and fludarabine in mouse models. Gene Ther. 9(12):2002;759-768
25. Both G. Xenogenic adenoviruses. In: Curiel D, Douglas J, (Eds.). Adenoviral vectors for gene therapy. Academic Press: San Diego, 2002; p. 447-79.
26. Encke J., zu Putlitz J., Geissler M., Wands J.R. Genetic immunization generates cellular and humoral immune responses against the nonstructural proteins of the hepatitis C virus in a murine model. J. Immunol. 161(9):1998;4917-4923
27. Gordon E.J., Bhat R., Liu Q., Wang Y.F., Tackney C., Prince A.M. Immune responses to hepatitis C virus structural and nonstructural proteins induced by plasmid DNA immunizations. J. Infect. Dis. 181(1):2000;42-50
28. Brinster C., Muguet S., Lone Y.C., Boucreux D., Renard N., Fournillier A., et al. Different hepatitis C virus nonstructural protein 3 (Ns3)-DNA-expressing vaccines induce in HLA-A2.1 transgenic mice stable cytotoxic T lymphocytes that target one major epitope. Hepatology. 34(6):2001;1206-1217
29. Lazdina U., Hultgren C., Frelin L., Chen M., Lodin K., Weiland O., et al. Humoral and CD4(+) T helper (Th) cell responses to the hepatitis C virus non-structural 3 (NS3) protein: NS3 primes Th1-like responses more effectively as a DNA-based immunogen than as a recombinant protein. J. Gen. Virol. 82(Pt 6):2001;1299-1308
30. Cho J.H., Lee S.W., Sung Y.C. Enhanced cellular immunity to hepatitis C virus nonstructural proteins by codelivery of granulocyte macrophage-colony stimulating factor gene in intramuscular DNA immunization. Vaccine. 17(9-10):1999;1136-1144